You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | 0.0% | n/a |
ROCE | 338.4% |
Latest | Forecast | |
---|---|---|
P/E | -0.6 | 0.0 |
PEG | 0.0 | -999,999.0 |
Price / Revenue | 0.0 | 0.0 |
Price / Book value | 5.9 |
Latest | Forecast | |
---|---|---|
Revenue | n/a | 0.0% |
PBT | 0.0% | n/a |
EPS | 0.0% | 0.0% |
DPS | n/a | 0.0% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2016-12-31 | n/a | -5.75 | -1,067.50p | -0.6 | 0.0 | n/a | n/a | 0.0% |
2017-12-31 | n/a | -3.55 | -237.50p | -2.3 | 0.0 | n/a | n/a | 0.0% |
2018-12-31 | n/a | -4.83 | -117.50p | -0.9 | 0.0 | n/a | n/a | 0.0% |
2019-12-31 | n/a | -2.72 | -32.50p | -0.5 | 0.0 | n/a | n/a | 0.0% |
Physiomics and ValiRx enter new collaboration deal Sharecast News | 15 Feb |
---|---|
ValiRx adds four new patents to portfolio in 2020 Sharecast News | 19 Jan |
ValiRx looks to build on portfolio of drug candidates Sharecast News | 06 Jul |
Total Voting Rights | 01-Mar-21 07:01 |
---|---|
Block listing Interim Review | 25-Feb-21 07:00 |
Director/PDMR Shareholding | 18-Feb-21 15:39 |
Extension of Collaboration Agreement | 15-Feb-21 07:00 |
Director Disclosure | 19-Jan-21 11:36 |